术中应用术前设计好3D模具设计截骨走形，置入截骨导板，精准截骨纠正患者距骨外翻力线，手术过 程顺利。术后假体位置及力线良好，肢体畸形明显纠正。 随着我国人口老龄化逐渐加重，踝关节炎患者增多，济宁市第一人民医院手外科足踝外科团队在成功完 成鲁西南第一例全踝关节置换术的基础上，持续创新，并通过率先运用3D打印定制技术，人工智能术 前规划与关节置换技术，攻克了传统手术中踝关节严重塌陷、踝关节畸形纠正的治疗难题，助力更多踝 关节疾病患者重塑行走的自由。 近日，济宁市第一人民医院手外科足踝外科主任曾文超教授团队成功应用3D打印技术，为一名77岁的 严重右侧踝关节骨性关节炎患者成功实施了3D打印全踝关节置换手术，比传统踝关节置换时间减少90 分钟，比术前踝关节活动度增加30度，标志着手外足踝外团队在关节重建领域迈入"个体化精准修复"新 阶段。 今年77岁的患者鲍先生，右踝关节疼痛8年余，踝关节疼痛逐渐加重，目前仅能行走100米就会出现疼痛 不能行走，因踝关节活动受限，不能上坡，严重影响了患者的日常活动。为求进一步治疗，患者来济宁 市第一人民医院手外科足踝外科就诊。详细沟通后，患者对关节活动度要求高，希望尽可能恢复正常行 ...

Investment Rating - The investment rating for the company is "Outperform the Market" [6][4]. Core Insights - In 2024, the company achieved a revenue of 1.346 billion (up 23.1%) and a net profit of 274 million (up 50.4%), driven by increased demand for orthopedic products and effective cost management [10][4]. - The company is focusing on expanding its overseas market presence and has seen significant growth in its international revenue, which reached 274 million (up 20.8%), accounting for 20.4% of total revenue [15][4]. - The company is leveraging its 3D printing technology and digital orthopedic solutions to create a comprehensive ecosystem, enhancing its competitive edge in the market [24][23]. Revenue and Profitability - The revenue from hip joint implants was 729 million (up 23.5%), and knee joint implants generated 405 million (up 30.1%) in 2024, indicating a strong recovery in surgical volumes [15][2]. - The gross profit margin for 2024 was 60.0%, with a net profit margin of 20.3%, reflecting effective cost control measures [20][3]. - The company has maintained a focus on research and development, with a R&D expense ratio of 10.3%, while also managing other expenses effectively [20][3]. Financial Forecasts - The company has slightly adjusted its profit forecasts for 2025-2026, now expecting net profits of 334 million, 404 million, and 484 million for 2025, 2026, and 2027 respectively, with growth rates of 21.9%, 20.8%, and 20.0% [4][5]. - The current price-to-earnings (PE) ratios are projected to be 19.2, 15.9, and 13.2 for 2025, 2026, and 2027 respectively, indicating a favorable valuation compared to historical performance [4][5]. Market Position and Strategy - The company is recognized as a leader in the orthopedic market, being the first in China to commercialize 3D printing technology for joint implants, which strengthens its market position [24][4]. - The strategic focus on digital orthopedic solutions and international expansion is expected to drive future growth, with the company successfully entering new markets [24][15].

报名：首届全球心血管大会 | 奖项申报 # 财报数据 报名：首届全球骨科大会 | 奖项评选 报名：首届全球眼科大会 | 议程更新 2024年公司 收入达13.46亿元人民币，同比增长23.1% 。公司权益股东应占年度溢利为2.74亿元，同比增长 50.4%。基本每股盈利0.25元，摊薄每股盈利0.24元。拟派发末期股息每股7.2港仙。 毛利达到约8.08亿元，增 长19.8% 。 合作伙伴征集：2025全球手术机器人大会 | 財務摘要 | | | | | --- | --- | --- | --- | | | 截至12月31日止年度 | | | | | 2024年 | 2023年 | 變動百分比 | | | 人民幣千元 | 人民幣千元 | 96 | | 收入 | 1,346,377 | 1,093,862 | 23.1% | | 毛利 | 808.193 | 674.486 | 19.8% | | 年内溢利 | 273,926 | 182,104 | 50.4% | | 本公司權益股東應佔年度溢利 | 273,926 | 182,104 | 50.4% | | 每股盈利 | | | | | 基本 | 人民幣0 ...